Potential of soluble CD26 as a serum marker for colorectal cancer detection
Authors:
- Oscar J CorderoOCOscar J Cordero
- Monica ImbernonMIMonica Imbernon
- Loretta De ChiaraLCLoretta De Chiara
- Vicenta S Martinez-ZorzanoVMVicenta S Martinez-Zorzano
- Daniel AyudeDADaniel Ayude
- Maria Paez De La CadenaMCMaria Paez De La Cadena
- F Javier Rodriguez-BerrocalFRF Javier Rodriguez-Berrocal
Open Access
- 1 January 2011
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 2 (6) , 245-261
Abstract
Colorectal cancer is characterized by a low survival rate even though the basis for colon cancer development, which involves the evolution of adenomas to carcinoma, is known. Moreover, the mortality rates continue to rise in economically transitioning countries although there is the opportunity to intervene in the natural history of the adenoma-cancer sequence through risk factors, screening, and treatment. Screening in particular accounted for most of the decline in colorectal cancer mortality achieved in the USA during the period 1975-2000. Patients show a better prognosis when the neoplasm is diagnosed early. Among the variety of screening strategies, the methods range from invasive and costly procedures such as colonoscopy to more low-cost and non-invasive tests such as the fecal occult blood test (guaiac and immunochemical). As a non-invasive biological serum marker would be of great benefit because of the performance of the test, several biomarkers, including cytologic assays, DNA and mRNA, and soluble proteins, have been studied. We found that the soluble CD26 (sCD26) concentration is diminished in serum of colorectal cancer patients compared to healthy donors, suggesting the potential utility of a sCD26 immunochemical detection test for early diagnosis. sCD26 originates from plasma membrane CD26 lacking its transmembrane and cytoplasmic domains. Some 90%-95% of sCD26 has been associated with serum dipeptidyl peptidase IV (DPP-IV) activity. DPP-IV, assigned to the CD26 cluster, is a pleiotropic enzyme expressed mainly on epithelial cells and lymphocytes. Our studies intended to validate this test for population screening to detect colorectal cancer and advanced adenomas are reviewed here.Keywords
This publication has 243 references indexed in Scilit:
- Vascular endothelial growth factor (VEGF) – a valuable serum tumour marker in patients with colorectal cancer?European Journal of Surgical Oncology, 2001
- Cd26/Dipeptidyl Peptidase IV in ContextJournal of Experimental Medicine, 1999
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996
- Decreases in the relative concentrations of specific hepatocyte plasma membrane proteins during liver regeneration: Down-regulation or dilution?Developmental Biology, 1991
- The application of leukocyte adherence inhibition assay to patients with colorectal cancerDiseases of the Colon & Rectum, 1989
- Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patientsBiochemical Medicine and Metabolic Biology, 1987
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986
- Serum glycylproline dipeptidyl aminopeptidase activity in human hepatic cancerClinica Chimica Acta, 1979
- Tube leukocyte adherence inhibition (LAI) assay in gastrointestinal (GIT) cancerCancer, 1979